The United Kingdom’s stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines amid weak trade data from China, impacting companies heavily reliant on global demand. In such an environment, identifying undervalued stocks becomes crucial as investors seek opportunities where market prices may not fully reflect a company’s intrinsic worth.
Name
Current Price
Fair Value (Est)
Discount (Est)
PageGroup (LSE:PAGE)
£2.27
£4.44
48.9%
LSL Property Services (LSE:LSL)
£2.80
£5.58
49.8%
Likewise Group (AIM:LIKE)
£0.28
£0.53
46.8%
Kromek Group (AIM:KMK)
£0.0485
£0.090
46.2%
Hollywood Bowl Group (LSE:BOWL)
£2.495
£4.82
48.2%
Gym Group (LSE:GYM)
£1.478
£2.90
49.1%
Gooch & Housego (AIM:GHH)
£5.50
£10.82
49.1%
Burberry Group (LSE:BRBY)
£11.05
£21.09
47.6%
AstraZeneca (LSE:AZN)
£117.94
£223.39
47.2%
ACG Metals (LSE:ACG)
£9.20
£17.32
46.9%
Let’s uncover some gems from our specialized screener.
Overview: ACG Metals Limited focuses on copper production in Europe and has a market cap of £199.26 million.
Operations: The company’s revenue is primarily derived from its mining segment, which generated $57.75 million.
Estimated Discount To Fair Value: 46.9%
ACG Metals is trading at £9.2, significantly below its estimated fair value of £17.32, indicating potential undervaluation based on cash flows. The company forecasts robust revenue growth of 28.4% annually, surpassing the UK market average and expects to become profitable within three years with a high return on equity projected at 29%. Despite recent production challenges, ACG upgraded its annual production guidance due to operational improvements and strategic leadership changes enhancing future prospects.
LSE:ACG Discounted Cash Flow as at Sep 2025
Overview: Dr. Martens plc is involved in the design, development, procurement, marketing, sale, and distribution of footwear and has a market cap of approximately £889.09 million.
Operations: The company’s revenue is primarily generated from its footwear segment, amounting to £787.60 million.
Estimated Discount To Fair Value: 17.5%
Dr. Martens is trading at £0.92, below its estimated fair value of £1.11, suggesting potential undervaluation based on cash flows. The company’s earnings are forecast to grow significantly at 46% annually, outpacing the UK market average. However, profit margins have declined from last year and the dividend yield of 2.77% is not well covered by earnings, raising sustainability concerns despite expected revenue growth surpassing the market’s rate slightly at 4.2%.
Story Continues